11.40

1.15% 0.13

Mink Therapeutics Inc (INKT)

Overview News Price History Financials Discussions Forecast

Mink Therapeutics Inc stock is traded at $11.40, with a volume of 5,203. It is up +1.15% in the last 24 hours and up +6.94% over the past month. MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Previous Close:

$11.27

Open:

$11.15

24h Volume:

5,203

Relative Volume:

0.21

Market Cap:

$57.09M

Revenue:

Net Income/Loss:

$-12.49M

P/E Ratio:

-3.8451

EPS:

-2.9648

Net Cash Flow:

$-5.93M

1W Performance:

+4.11%

1M Performance:

+6.94%

6M Performance:

+1.97%

1Y Performance:

-23.54%

1-Day Range:

$11.06

$11.45

1-Week Range:

$10.82

$11.60

52-Week Range:

$8.4801

$16.98

Mink Therapeutics Inc Stock (INKT) Company Profile

Name

Mink Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

212-994-8250

Address

149 FIFTH AVENUE, NEW YORK

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

INKT's Discussions on Twitter

Compare INKT vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INKT Mink Therapeutics Inc	11.19	57.51M	0	-12.49M	-5.93M	-2.9648
VRTX Vertex Pharmaceuticals Inc	515.50	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.71	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.46	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.24	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.25	39.31B	5.76B	514.49M	1.10B	4.4813

Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-14-25	Downgrade	William Blair	Outperform → Mkt Perform

Mink Therapeutics Inc Stock (INKT) Latest News

Aug 14, 2026

MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm

Aug 14, 2026

H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo

Aug 14, 2026

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - MarketBeat

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Ryan Barbara	Director	Mar 10 '26	Sale	15.40	1,300	20,017	20,406
Ryan Barbara	Director	Mar 09 '26	Sale	10.17	200	2,034	21,706
Ryan Barbara	Director	Feb 27 '26	Sale	10.86	400	4,343	22,006
Ryan Barbara	Director	Mar 02 '26	Sale	10.83	100	1,083	21,906

Mink Therapeutics Inc (INKT)

Mink Therapeutics Inc Stock (INKT) Company Profile

Compare INKT vs VRTX, REGN, ARGX, RVMD, ONC

Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades

Mink Therapeutics Inc Stock (INKT) Latest News

MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm

H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - MarketBeat

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.com

MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat

MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research SymposiumSlideshow - Seeking Alpha

MiNK Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

META_TITLE_QUOTE - Yahoo Finance

MiNK Therapeutics Q2 Earnings Call Highlights - MarketBeat

MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M - scanx.trade

INKT: Advanced phase II ARDS trial and global access for agenT-797, with stable financials - TradingView

MiNK Therapeutics (INKT.US) will release its earnings report after market close on August 13. - 富途牛牛

Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances - Investing.com

Transcript : MiNK Therapeutics, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com

INKT: Phase II trial for agenT-797 in ARDS shows early promise; global access and financial discipline maintained - TradingView

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - Investing News Network

Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Australia

MiNK Therapeutics reports Phase 2 trial data for agenT-797 - Investing.com

MiNK Reports $3.1 Million Second-Quarter Loss and Phase 2 ARDS Update - Quiver Quantitative

MiNK Therapeutics Q2 loss narrows on expense discipline - TradingView

MiNK Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire

Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Mink Therapeutics Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - Investing News Network

MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia - Blockonomi

Transactions récentes par des initiés de Mink Therapeutics Inc. R (6Q40.F) - Yahoo Finance France

MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium - GlobeNewswire

Liquidity Mapping Around (INKT) Price Events - Stock Traders Daily

MiNK Therapeutics to Report Second Quarter 2026 Financial Results and Provide Corporate Update on agenT-797 Clinical Progress - Quiver Quantitative

MiNK Therapeutics to Report Second Quarter 2026 Financial - GlobeNewswire

New agenT-797 lung-injury data due from MiNK Aug. 13 - Stock Titan

MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday - MarketBeat

Mink Therapeutics to report Q2 results, host conference call and webcast - Bitget

INKT Q2'26 Earnings: revenue estimate is 0 USD - TradingView

MiNK Therapeutics (INKT) Climbs 5.7% as Biotech Momentum BuildsStraddle Setup - dars.gov.et

MiNK Therapeutics Q1 2026 Earnings: Narrower Loss than Expected Reflects Cost DisciplineQuarterly Earnings - dars.gov.et

Mink Therapeutics Inc (INKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Mink Therapeutics Inc (INKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Mink Therapeutics Inc (INKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com

Mink Therapeutics Inc (INKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

INKT|Mink Therapeutics Inc|Price:11.070|Chg%:+0.700 - TradingKey

TradingKey - TradingKey

Mink Therapeutics Inc (INKT) Balance Sheet - TradingKey

Mink Therapeutics Inc (INKT) Income Statement - TradingKey

MiNK Therapeutics, Inc. Revenue Breakdown – FWB:6Q40 - TradingView

Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis - TradingKey

Mink Therapeutics Inc (INKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

MiNK Therapeutics, Inc. Revenue Breakdown – MUN:6Q40 - TradingView

INKT|Mink Therapeutics Inc|Price:10.600|Chg%:-0.470 - TradingKey

Mink Therapeutics Inc Stock (INKT) Financials Data

Revenue

Net Income

Cash Flow

EPS

Mink Therapeutics Inc Stock (INKT) Insider Trading

Similar to INKT